Our new Annual Report has been released!  It's packed with info on our research projects, education programs, and outreach activities - and on Project|21, designed to move rejuvenation biotechnology into human clinical trials by 2021.

Check out all the latest news from SENS Research Foundation in our June newsletter. You might also like to check out the archive of past messages, or subscribe to our mailing list to make sure you don't miss out on future updates!

Zoomer Radio's Michael Kramer caught up with Dr. de Grey after his talk at Ideacity 2017, and took the chance to discuss recent progress in rejuvenation medicine and the remaining obstacles on the path to healthier, longer lives.

SRF's third new collaboration with the Buck Institute for Research on Aging is focused on developing a major improvement in gene therapy techniques. Hosted in Dr. Brian Kennedy's laboratory, the project will enable safer gene editing for future clinical work.

We're delighted to announce another new collaboration with the Buck Institute for Research on Aging: Dr. Judith Campisi will host a project seeking ways to eliminate senescent immune cells, which contribute to a vicious cycle of age-related decline in immune function.

Tad Friend of The New Yorker presents a wide-ranging review of the various initiatives currently under way to extend healthy human lifespans - discussing the work of SENS Research Foundation, Google's Calico, Unity Biotechnology, and many others.

Ichor Therapeutics is seeking Series A funding for Phase I trials of LYSOCLEAR: the first potential cure for the more than 20 million Americans suffering from AMD (the leading cause of vision loss in those over 50), and the first clinical candidate based on the SENS paradigm.

We're proud to announce a new collaboration with the Buck Institute for Research on Aging's Dr. Julie Andersen, a leading expert on neurodegeneration. The project will focus on clearing tangles of tau protein - a key driver of Alzheimer's and similar diseases.

As part of Google's Giving Week, MitoSENS project leader Dr. Matthew O'Connor gave a Tech Talk on December 9th introducing SRF and our "damage repair" approach to fighting aging - followed by an update on our progress in repairing defective mitochondria.

Surgically connecting young and old mice reverses some aspects of aging, but isn't practical for humans! Fortunately for us, new SRF-funded work shows that transfusions of young blood produce many of the same benefits - paving the way towards human trials.

Deleting senescent cells from mice delays many age-related diseases. A recent paper from the Unity Biotechnology team, who aim to start human trials in 12-18 months, now identifies atherosclerosis as another deadly condition which may be prevented by senolytic drugs.

A recent demographic analysis in Nature by Vijg et al. has attracted global attention after concluding that there is a "natural limit" of around 115 years to human lifespans - but has also been criticised for undue pessimism regarding future medical advances.

Project|21's first patron, German internet entrepeneur Michael Greve, has formally announced a list of the research efforts that will be supported over the next year by the initial $1m tranche of his donation - as well as the startup companies receiving seed funds.

SENS Research Foundation has commissioned a series of 8 animations, narrated by actor Edward James Olmos, to explain the concept of SENS and some of the therapies that we're developing to end age-related disease for good.

Michael Greve, the first donor to our Project|21 campaign, gave a presentation at RB2016 discussing how his life led to a passionate interest in the long-term maintenance of human health - and ultimately his decision to commit $10 million to our work.

Entrepreneur and biohacker Dave Asprey recently interviewed our Chief Science Officer, Dr. Aubrey de Grey, for the health podcast Bulletproof Radio. Their in-depth conversation covers a broad range of topics related to our current work and future plans.

A new article in Genetic Engineering & Biotechnology News explores how applying regenerative medicine to the accumulated damage of aging is becoming an increasingly mainstream idea, crediting SRF CSO Aubrey de Grey as a pioneer in the field.